More importantly, when injected into the mouse xenograft tumor model of human B-cell malignancy, these modified CD19 CAR T cells exhibited not only enhanced in vivo persistence and proliferation but also showed improved long-term antitumor efficacy in vivo. Here, CD19 is linked to neoplasm.